Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical impact of low serum free T4 in patients with non-small cell lung cancer treated with nivolumab.

Scientific reports - 19 Nov 2019

Funazo Tomoko Yamamoto, Nomizo Takashi, Ozasa Hiroaki, Tsuji Takahiro, Yasuda Yuto, Yoshida Hironori, Sakamori Yuichi, Nagai Hiroki, Hirai Toyohiro, Kim Young Hak

Abstract excerpt

Nivolumab improves the prognosis of non-small cell lung cancer (NSCLC) but can cause immune-related adverse events (irAEs). Reports have indicated longer progression-free survivals (PFSs) in patients with irAEs than in those without irAEs. We reported associations between programmed death ligand-1 (PD-L1) single nucleotide polymorphisms (SNPs) and PFS after nivolumab treatment. We hypothesized that adverse events...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Immunological
Share to B7-H1 Antigen

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug-Related Side Effects and Adverse Reactions

Share to Nivolumab

Share to Programmed Cell Death 1 Receptor

Share to Survival Rate

Share to Thyroid Function Tests

Share to Thyroxine

Source

Open in PubMed Open full text

Identifiers

PMID: 31745135
DOI: 10.1038/s41598-019-53327-7
PMCID: PMC6864095

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 9 closest

Clinical impact of low serum free T4 in patients with non-small cell lung cancer treated with nivolumab.PMID 31745135Read ↗

Clinical Impact of Single Nucleotide Polymorphism in PD-L1 on Response to Nivolumab for Advanced Non-Small-Cell Lung Cancer Patients.Semantic proximity Read ↗

PD-L1 polymorphisms predict survival outcomes in advanced non-small-cell lung cancer patients treated with PD-1 blockade.Semantic proximity Read ↗

Association Between Genetic Variants and the Risk of Nivolumab-Induced Immune-Related Adverse EventsSemantic proximity Read ↗

Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment.Semantic proximity Read ↗

Immunological Status May Predict Response to Nivolumab in Non-small Cell Lung Cancer without Driver Mutations.Semantic proximity Read ↗

Association between single-nucleotide polymorphisms and adverse events in nivolumab-treated non-small cell lung cancer patients.Semantic proximity Read ↗

A Multivariable Regression Model-based Nomogram for Estimating the Overall Survival of Patients Previously Treated With Nivolumab for Advanced Non-small-cell Lung Cancer.Semantic proximity Read ↗

EGFR-TKI-Associated Interstitial Pneumonitis in Nivolumab-Treated Patients With Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Severe Immune-Related Adverse Events in Patients Treated with Nivolumab for Metastatic Renal Cell Carcinoma Are Associated with PDCD1 PolymorphismSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.